NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Co (BMY) and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology (I-O) target.
QIMR Berghofer Medical Research Institute is a translational research institute focused on cancer, infectious diseases, mental health and a range of complex disorders. Bristol-Myers Squibb will be solely responsible for clinical development and commercialization of antibodies discovered through the collaboration. Financial terms were not disclosed.
'Bristol-Myers Squibb continues to invest in strategic partnerships that accelerate the discovery and development of novel immunotherapies through innovative science and technologies,' said Carl Decicco, Head of Discovery, R&D, Bristol-Myers Squibb. 'We are excited to work with QIMR Berghofer Medical Research Institute, a partner that brings significant experience and expertise in cancer research.'
Copyright RTT News/dpa-AFX